Loading patent…
AssigneeUniversity of Virginia Patent Foundation
InventorsBenjamin Purow, Desiree Floyd, Inan Olmez, Thurl E. Harris, Jr., Salome Boroda
Estimating the term…
Ritanserin is shown to be an inhibitor of diacylglycerol kinase alpha (DGKα) and to be cytotoxic to glioblastoma and melanoma cells. Ritanserin treatment also provides chemo- and radiosensitization in cancer cells, prolonged survival in mouse models of glioblastoma, decreased melanoma tumor burden in mice, and shows synergistic cytotoxic effects with temozolomide and chloroquine, both singly and in combination. DGKα inhibition with ritanserin shows particular toxicity to the treatment-resistant mesenchymal subtype in glioblastoma and other cancers.
A method for treating a cancer in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of ritanserin, wherein the cancer is selected from the group consisting of mesenchymal cancer, melanoma and glioblastoma.
A method of inducing chemo- or radiosensitivity in a subject undergoing or scheduled to undergo treatment with a chemotherapeutic agent or radiation to treat a disease or disorder treatable thereby, the method comprising administering ritanserin to the subject, wherein the disease or disorder is selected from the group consisting of mesenchymal cancer.
A method for inhibiting a cancer in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of ritanserin, wherein the cancer is a melanoma or a glioblastoma.
Dependencies are inferred from the claim text.